13466-38-1

Basic information

• Product Name: 2-Hydroxy-5-bromopyridine
• Synonyms: 2-Hydroxy-5-bromopyridine ,97%;2-Hydroxy-5-broMopyridine, 99% 25GR;2-Hydroxy-5-broMopyridine, 99% 5GR;5-Bromo-2-pyridinol 5-Bromo-2(1H)-pyridinone 5-Bromo-2-pyridone;5-Bromopyridin-2-ol, 5-Bromopyridin-2(1H)-one;2-hydroxy -5-pyridyl broMide;5-BroMo-1H-pyridin-2-one;5-Bromo-2(1H)-pyridone 97%
• CAS NO: 13466-38-1
• Molecular Formula: C₅H₄BrNO
• Molecular Weight: 174
• EINECS: -0
• Product Categories: blocks;Bromides;Pyridines;Pyridine;Alcohols and Derivatives;Heterocycles;Pyridine Series;Halides;Bromopyridines;Halopyridines;C5Heterocyclic Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks
• Mol File: 13466-38-1.mol
• Article Data: 24

Chemical Properties

• Melting Point: 180-183 °C(lit.)
• Boiling Point: 305.9 ºC at 760 mmHg
• Flash Point: 138.8 ºC
• Appearance: Off-white to yellow-brown/Crystalline Powder
• Density: 1.776 g/cm³
• Vapor Pressure: 0.000796mmHg at 25°C
• Refractive Index: 1.6
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 9.96±0.10(Predicted)
• BRN: 108751
• CAS DataBase Reference: 2-Hydroxy-5-bromopyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Hydroxy-5-bromopyridine(13466-38-1)
• EPA Substance Registry System: 2-Hydroxy-5-bromopyridine(13466-38-1)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-36-22
• Safety Statements: 26-37/39-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 13466-38-1(Hazardous Substances Data)

Usage

Chemical Properties

off-white to yellow-brown crystalline powder

General Description

5-Bromo-2(1H)-pyridone undergoes difluormethylation in the presence of sodium chlorodifluoroacetate (ClCF2COONa) and methyl cyanide.

InChI:InChI=1/C5H4BrNO/c6-4-1-2-5(8)7-3-4/h1-3H,(H,7,8)

Upstream product

• 624-28-2 2,5-dibromopyridine 
• 142-08-5 2-hydroxypyridin 
• 13472-85-0 2-methoxy-5-bromopyridine 
• 122256-50-2 1-benzyloxy-5-bromo-2-pyridone 
• 53939-30-3 5-bromo-2-chloropyridine 
• 109-09-1 2-chloropyridine 
• 1072-97-5 5-bromo-2-pyridylamine 
• 1493-13-6 trifluorormethanesulfonic acid 
• 504-29-0 2-aminopyridine 
• 83664-33-9 2-(benzyloxy)-5-bromopyridine 
• 39856-50-3 5-bromo2-nitropyridine 
• 51933-78-9 5-bromo-2-(methylsulfanyl)pyridine 
• 856849-02-0 2-benzyloxy-5-bromo-pyridine-1-oxide 

Downstream Products

• 189954-65-2 3-[(5-bromo-2-pyridinyl)oxy]-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone 
• 381233-75-6 5-bromo-2-hydroxy-3-iodopyridine 
• 870521-31-6 5-bromo-2-isopropoxy-pyridine 
• 879892-41-8 1-(4-chloro-2-fluorobenzyl)-5-bromopyridin-2(1H)-one 
• 18108-77-5 5-phenylsulfanylpyridin-2(1H)-one 
• 851087-08-6 5-bromo-1-isopropylpyridine-2(1H)-one 
• 1621333-00-3 tert-butyl (3S)-3-(benzyl((1R)-1-phenylethyl)amino)-3-(6-(difluoromethoxy)pyridin-3-yl)propanoate 
• 381233-75-6 5-bromo-3-iodo-1,2-dihydropyridin-2-one 
• 56673-34-8 5-bromo-2-mercaptopyridine 
• 15862-34-7 5-bromo-3-nitro-1H-pyridin-2-one 
• 494771-68-5 5-bromo-2-(cyclopentyloxy)pyridine 
• 431942-34-6 2-(5-methoxy-2-phenylfuro[2,3-b]pyridin-3-yl)acetonitrile 
• 431942-32-4 3-bromo-2-methoxyfuro[2,3-b]pyridine 
• 431942-33-5 5-methoxy-3-methyl-2-phenylfuro[2,3-b]pyridine 

Relevant articles and documents

Design, synthesis, and biological activity evaluation of a series of novel sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia

Accumulating researches have contributed much effect to discover novel chemotherapeutic drug for leukemia with expeditious curative effect, of which bromodomain-containing protein 4 (BRD4) inhibitor is considered as a eutherapeutic drug which has presented efficient cell proliferation suppression effect. In this study, we disclosed a series of phenylisoxazole sulfonamide derivatives as potent BRD4 inhibitors. Especially, compound 58 exhibited robust inhibitory potency toward BRD4-BD1 and BRD4-BD2 with IC50 values of 70 and 140 nM, respectively. In addition, compound 58 significantly suppressed cell proliferation of leukemia cell lines HL-60 and MV4-11 with IC50 values of 1.21 and 0.15 μM. In-depth study of the biological mechanism of compound 58 exerted its tumor suppression effect via down-regulating the level of oncogene c-myc. Moreover, in vivo pharmacokinetics (PK) study was conducted and the results demonstrated better pharmacokinetics features versus (+)-JQ1. In summary, our study discovers that compound 58 represents as a novel BRD4 inhibitor for further investigation in development of leukemia inhibitor with potentiality.

Preparation method of 2, 5-dibromopyridine

The invention discloses a preparation method of 2, 5-dibromopyridine, and belongs to the technical field of organic synthesis. The preparation method comprises the following steps: reacting 2-hydroxypyridine serving as a raw material with a bromination reagent to obtain 2-hydroxy-5-bromopyridine; and then reacting with a bromination reagent under the action of a Lewis acid catalyst to obtain 2, 5-dibromopyridine. The method is completed in two steps, an isomer obtained in the first step of reaction does not need to be purified, and a product with the purity of 99.5% or above can be obtained through recrystallization once in the last step.

PYRIDONE DERIVATIVE COMPRISING HETEROATOMIC RING BUTANE SUBSTITUENT, FOR TREATING FIBROSIS AND INFLAMMATORY DISEASES

Disclosed is a compound for treating fibrosis-related diseases, and specifically disclosed are the compound represented by formula (I) and a pharmaceutically acceptable salt thereof.